Company news
Denali Therapeutics Inc. news in 2021
Denali Therapeutics Inc.'s news releases, calls and decks from 2021, newest first.
Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop and Co-Commercialize DNL593 (PTV: PGRN)
November 16, 2021
Denali Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
November 3, 2021
Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS)
October 5, 2021
Denali Therapeutics Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting
September 28, 2021
Denali Therapeutics Appoints Katie Peng as Chief Commercial Officer
September 26, 2021
Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS
September 8, 2021
Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN
August 25, 2021
Denali Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
August 3, 2021
Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV: IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)
July 24, 2021
Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV: IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021
July 14, 2021
Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in Cutaneous Lupus Erythematosus (CLE) Patients
June 27, 2021
Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
May 2, 2021
Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease
April 30, 2021
Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer
March 29, 2021
Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV: IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)
March 10, 2021
Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights
February 24, 2021
Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV: IDS (DNL310) in Patients with Hunter Syndrome (MPS II)
February 11, 2021
Denali Therapeutics to Present New Data on ETV: IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™
February 4, 2021
Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors
January 10, 2021
Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration
January 7, 2021